Regeneron Pharmaceuticals Inc (REGN)

402.02
4.34 1.07
NASDAQ : Health Care
Prev Close 406.36
Open 396.44
Day Low/High 390.56 / 404.98
52 Wk Low/High 329.09 / 605.93
Volume 1.11M
Avg Volume 762.00K
Exchange NASDAQ
Shares Outstanding 105.29M
Market Cap 44.13B
EPS 6.20
P/E Ratio 65.38
Div & Yield N.A. (N.A)

Latest News

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc.

Allergan's Dealmaking Continues With Vitae Takeout

Allergan's Dealmaking Continues With Vitae Takeout

The $639 million deal marks the the third purchase for Brent Saunders since early August.

Regeneron Pharmaceuticals Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Sirius XM Holdings

Regeneron Pharmaceuticals Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Sirius XM Holdings

The most recent short interest data has been released for the 08/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

How Will Regeneron (REGN) Stock React to Cholesterol Drug Trial Success?

How Will Regeneron (REGN) Stock React to Cholesterol Drug Trial Success?

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Regeneron Announces Agreement With BARDA For The Manufacturing And Testing Of New Antibodies Against MERS Virus

Regeneron Announces Agreement With BARDA For The Manufacturing And Testing Of New Antibodies Against MERS Virus

A component of Regeneron's Rapid Response program, which is also targeting Zika and Ebola

Regeneron Pharmaceuticals Becomes #39 Most Shorted Nasdaq 100 Component, Replacing JD.com

Regeneron Pharmaceuticals Becomes #39 Most Shorted Nasdaq 100 Component, Replacing JD.com

The most recent short interest data has been released for the 07/29/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVG, CIT, CRNT, CX, EGL, FOE, GOOD, ISNS, KRNT, KTEC, LBY, LPX, MIXT, MPC, MTSI, NATR, NVTA, REGN, SSTK Downgrades: CBPX, DVA, FCFP, ITG, PBH, STN Initiations: CFMS, JCAP, LILA, LILAK, NIHD, PYPL Read on to get TheStreet Quant Ratings' detailed report:

CMCSA, IDXX, ZTS: Jim Cramer's Views

CMCSA, IDXX, ZTS: Jim Cramer's Views

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Unusual Social Activity Around Regeneron Pharmaceuticals (REGN) Today

Unusual Social Activity Around Regeneron Pharmaceuticals (REGN) Today

Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as an unusual social activity candidate

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts

The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.

Regeneron And Adicet Bio Announce Strategic Collaboration To Discover And Develop Next-Generation Engineered Immune Cell Therapeutics

Regeneron And Adicet Bio Announce Strategic Collaboration To Discover And Develop Next-Generation Engineered Immune Cell Therapeutics

Regeneron and Adicet to pursue "off-the-shelf" cellular therapies in oncology

3 Stocks Boosting The Health Care Sector Higher

3 Stocks Boosting The Health Care Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Jim Cramer: I’m Looking at the Biotechs

Jim Cramer: I’m Looking at the Biotechs

Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.

Jim Cramer -- Celgene Igniting a Rally in Biotech

Jim Cramer -- Celgene Igniting a Rally in Biotech

The biotech sector was a great short throughout the year, but that trade appears to be over, Cramer said.

Regeneron Is Regenerating Lost Profits

Regeneron Is Regenerating Lost Profits

Investors should risk below $380 for now.

Regeneron Pharmaceuticals Becomes #185 Most Shorted S&P 500 Component, Replacing Republic Services

Regeneron Pharmaceuticals Becomes #185 Most Shorted S&P 500 Component, Replacing Republic Services

The most recent short interest data has been released for the 07/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

3 Drugs Stocks Pushing Industry Growth

3 Drugs Stocks Pushing Industry Growth

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

3 Stocks Driving The Health Care Sector Higher

3 Stocks Driving The Health Care Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Regeneron Pharmaceuticals Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Vertex Pharmaceuticals

Regeneron Pharmaceuticals Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Vertex Pharmaceuticals

The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.